Dr. David VanderWeele
Claim this profileNorthwestern University
Studies Prostate Cancer
Studies Thyroid Cancer
13 reported clinical trials
35 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
2Thyroid Cancer
Stage IV
TFEb positive
TFE3 positive
Affiliated Hospitals
Clinical Trials David VanderWeele is currently running
FDG-PET-Guided Radiation Therapy
for Prostate Cancer
This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate cancer that is sensitive to androgen-deprivation therapy (ADT) and has spread from where it first started (primary site) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer death among men in the United States, despite the approval of several life-prolonging treatments by the Food and Drug Administration. However, over the past 10 years, there have been significant improvements in prolonging the lives of those with metastatic hormone sensitive prostate cancer, specifically by adding treatments to standard therapy, such as ADT. More recently, trials have demonstrated a benefit of using radiotherapy (high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors) to delay the progression of cancer and prolong life for patients with metastatic disease. Imaging scans with FDG-PET may be able to identify cancer sites that remain active despite standard treatment. Giving MDRT plus standard treatment to patients with FDG-PET-identified cancer sites may work better than standard treatment alone in treating metastatic hormone sensitive prostate cancer.
Recruiting1 award Phase 2
Darolutamide vs Enzalutamide
for Prostate Cancer
This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with metastatic and non-metastatic castration resistant prostate cancer (CRPC) or metastatic hormone sensitive prostate cancer (HSPC). Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg orally daily or darolutamide 600 mg orally twice daily, in combination with standard LHRH agonist based treatment. Cognitive assessments will be performed using modules from Cambridge Neuropsychological Test Automated Battery (CANTAB) an internationally recognized software for assessing cognitive function and impairment.
Recruiting1 award Phase 2
More about David VanderWeele
Clinical Trial Related6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments David VanderWeele has experience with
- Carboplatin
- Prednisone
- Nivolumab
- Cabazitaxel
- Abiraterone Acetate
- Enzalutamide
Breakdown of trials David VanderWeele has run
Prostate Cancer
Thyroid Cancer
- Abiraterone + Antiandrogen +/- Chemotherapy for Advanced Prostate Cancer
- FDG-PET-Guided Radiation Therapy for Prostate Cancer
- Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
Bladder Cancer
- Durvalumab + Chemo/Radiation for Bladder Cancer
- Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
- Blood Test and Immunotherapy for Bladder Cancer
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David VanderWeele specialize in?
David VanderWeele focuses on Prostate Cancer and Thyroid Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is David VanderWeele currently recruiting for clinical trials?
Yes, David VanderWeele is currently recruiting for 3 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that David VanderWeele has studied deeply?
Yes, David VanderWeele has studied treatments such as Carboplatin, Prednisone, Nivolumab.
What is the best way to schedule an appointment with David VanderWeele?
Apply for one of the trials that David VanderWeele is conducting.
What is the office address of David VanderWeele?
The office of David VanderWeele is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.